EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial

Marijn A Vermeulen iD, Linde M Amelung, Otilia Kimpel, Ulrich Dischinger, Vittoria Basile, Darko Kastelan iD, Hélène Lasolle, Isabelle Bourdeau, Svenja Nölting, Paola Loli iD, Magalie Haissaguerre, Alfredo Berruti iD und 3 weitere

Cancers · 18.08.2026 · 18 (16) · 2678

DOI: 10.3390/cancers18162678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.08.2026. Verfasst von Marijn A Vermeulen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, 3584CS Utrecht, The Netherlands. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Medicines Agency, German Research Foundation, PHRC-K.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Adrenocortical carcinoma (ACC) is a rare tumor. Diagnosis relies on combined histopathological criteria that, in a multifactorial scoring system, may suggest malignancy. The recent ADIUVO trial, a multicenter trial randomizing ACC patients between mitotane treatment or surveillance only, demonstrated that patients with localized, low-grade ACC (Ki67 labeling index (LI) ≤ 10%) have a better prognosis than historically anticipated, questioning the routine use of adjuvant mitotane. This post hoc analysis aimed to investigate whether automated, centralized Ki67 LI assessment improves prognostic stratification beyond expert manual assessment in low-risk ACC patients enrolled in the original ADIUVO trial.

Methods

Ki67 LI was centrally reassessed in 70 ADIUVO patients by digitizing slides and applying an automated algorithm to manually selected hotspots. Primary endpoints were correlation between methods and the impact of automated scoring on recurrence-free survival (RFS) and overall survival (OS).

Results

Automated Ki67 LI assessment was feasible in 47 patients. Manual and automated Ki67 LI values showed good agreement (mean 5.6 ± 3.1% vs. 5.4 ± 5.3%). Automated scoring identified eight patients with KI67 LI > 10%. In this subgroup, RFS and OS did not differ significantly between patients treated with mitotane and those under surveillance. Patients with an automated Ki67 LI > 10% had larger tumors (median 16.0 cm vs. 7.0 cm, p = 0.003).

Conclusions

Our findings support the original ADIUVO results and support continued use of manual expert Ki67 LI scoring. This traditional approach remains robust and pragmatic for most clinical settings, especially where automated systems are not readily accessible.

Schlagwörter

Stichwörter der Autor:innen

Ki67adrenocortical carcinomaprognosisrecurrencesurvival

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, 3584CS Utrecht, The Netherlands.
  • University Medical Center Utrecht, 3584CX Utrecht, The Netherlands.
  • Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital, University of Wurzburg, 97080 Wurzburg, Germany.
  • Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy.
  • Department of Endocrinology, University Hospital Zagreb, 10000 Zagreb, Croatia.
  • Federation d'Endocrinologie, Hospices Civils de Lyon, University de Lyon, 69500 Bron, France.

ORCID-Profile: Marijn A Vermeulen, Darko Kastelan, Paola Loli, Alfredo Berruti, Martin Fassnacht, Massimo Terzolo, Ronald R de Krijger

Förderung

  • Italian Medicines Agency
  • German Research Foundation
  • PHRC-K
  • Associazione Italiana per la Ricerca sul Cancro
  • ENS@T
  • Deutsche Forschungsgemeinschaft
  • French Ministry of Health

Zitieren

APA

Vermeulen, M. A., Amelung, L. M., Kimpel, O., Dischinger, U., Basile, V., Kastelan, D., Lasolle, H., Bourdeau, I., Nölting, S., Loli, P., Haissaguerre, M., Berruti, A., Fassnacht, M., Terzolo, M., & de Krijger, R. R. (2026). Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial. Cancers, 18(16), 2678. https://doi.org/10.3390/cancers18162678

Vancouver

Vermeulen MA, Amelung LM, Kimpel O, Dischinger U, Basile V, Kastelan D, et al. Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial. Cancers. 2026;18(16):2678. doi:10.3390/cancers18162678

BibTeX
@article{Vermeulen2026,
  author = {Vermeulen, Marijn A and Amelung, Linde M and Kimpel, Otilia and Dischinger, Ulrich and Basile, Vittoria and Kastelan, Darko and Lasolle, Hélène and Bourdeau, Isabelle and Nölting, Svenja and Loli, Paola and Haissaguerre, Magalie and Berruti, Alfredo and Fassnacht, Martin and Terzolo, Massimo and de Krijger, Ronald R},
  title = {Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2678},
  doi = {10.3390/cancers18162678}
}
Kostenlos starten →